Prosecution Insights
Last updated: April 19, 2026

Examiner: GEORGE, DENNIS CHERIAN

Tech Center 1600 • Art Units: 1644

This examiner grants 25% of resolved cases

Performance Statistics

25.0%
Allow Rate
-35.0% vs TC avg
25
Total Applications
-25.0%
Interview Lift
992
Avg Prosecution Days
Based on 8 resolved cases, 2023–2026

Rejection Statute Breakdown

2.5%
§101 Eligibility
18.8%
§102 Novelty
24.9%
§103 Obviousness
26.9%
§112 Clarity

Currently Pending Office Actions

App #TitleStatusAssignee
17702439 METHODS AND COMPOSITIONS FOR TREATING CANCER Non-Final OA President and Fellows of Harvard College
17473083 METHODS AND COMPOSITIONS FOR TREATING CANCER Non-Final OA President and Fellows of Harvard College
19210620 PSMA ANTIBODIES AND USES THEREOF Non-Final OA Wuxi Biologics Ireland Limited
17691182 Safe and Effective Method of Treating Psoriatic Arthritis with Anti-IL23 Specific Antibody Non-Final OA Janssen Biotech, Inc.
17599135 ENGINEERED ANTIBODIES Final Rejection DANISCO US INC
17771271 ANTI-TSLP ANTIBODY AND USES THEREOF Non-Final OA HARBOUR BIOMED (SHANGHAI) CO., LTD.
17422193 SGLT-2 INHIBITORS OR IL-1R ANTAGONISTS FOR REDUCTION OF HYPOGLYCAEMIA AFTER BARIATRIC SURGERY Final Rejection UNIVERSITÄTSSPITAL BASEL

Facing This Examiner?

IP Author analyzes examiner patterns and generates tailored response strategies with the highest chance of allowance.

Build Your Strategy

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month